结缔组织病相关肺动脉高压的治疗策略与生存:一项COMPERA分析
基于欧洲COMPERA注册研究分析607例新诊断结缔组织病相关肺动脉高压(CTD-PAH)患者,评估治疗模式与生存。SSc-PAH患者生存显著差于其他CTD-PAH(多变量校正后P=0.001);SSc-PAH中初始内皮素受体拮抗剂(ERA)联合磷酸二酯酶5抑制剂(PDE5i)治疗生存优于单药治疗(P=0.016和P=0.012)。
要点
- SSc-PAH患者1、3、5年生存率分别为85%、59%、42%,显著差于其他CTD-PAH(P=0.001)。
- SSc-PAH初始ERA-PDE5i联合治疗生存显著优于初始ERA单药(P=0.016)或PDE5i单药(P=0.012)。
- CTD-PAH总体死亡率仍高,尤其SSc-PAH患者。
核心结论
- CTD-PAH患者死亡率仍高,尤其是SSc-PAH患者。
- 对于SSc-PAH患者,结果提示初始ERA-PDE5i联合治疗较初始单药治疗可能改善长期生存。
研究设计与样本
- 分析欧洲肺动脉高压注册研究COMPERA数据,纳入607例新诊断CTD-PAH患者,描述治疗策略与生存。
- 按基础CTD类型分析全因死亡率;SSc-PAH患者另按初始ERA、PDE5i或两药联合治疗评估生存。
主要发现
- SSc-PAH(n=390)1、3、5年生存率分别为85%、59%、42%。
- SLE-PAH(n=34)1、3、5年生存率分别为97%、77%、61%。
- MCTD-PAH(n=33)1、3、5年生存率分别为97%、70%、59%。
- UCTD-PAH(n=60)1、3、5年生存率分别为88%、67%、52%。
- 其他CTD-PAH(n=90)1、3、5年生存率分别为92%、69%、55%;多变量校正后SSc-PAH生存显著差于其他情况(P=0.001)。
关键数值与推荐
- SSc-PAH初始ERA-PDE5i联合治疗生存显著优于初始ERA单药(P=0.016)和初始PDE5i单药(P=0.012)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Pulmonary arterial hypertension (PAH) occurs in various connective tissue diseases (CTDs). We sought to assess contemporary treatment patterns and survival of patients with various forms of CTD-PAH. METHODS: We analysed data from COMPERA, a European pulmonary hypertension registry, to describe treatment strategies and survival in patients with newly diagnosed PAH associated with SSc, SLE, MCTD, UCTD and other types of CTD. All-cause mortality was analysed according to the underlying CTD. For patients with SSc-PAH, we also assessed survival according to initial therapy with endothelin receptor antagonists (ERAs), phosphodiesterase type 5 inhibitors (PDE5is) or a combination of these two drug classes. RESULTS: This analysis included 607 patients with CTD-PAH. Survival estimates at 1, 3 and 5 years for SSc-PAH (n = 390) were 85%, 59% and 42%; for SLE-PAH (n = 34) they were 97%, 77% and 61%; for MCTD-PAH (n = 33) they were 97%, 70% and 59%; for UCTD-PAH (n = 60) they were 88%, 67% and 52%; and for other CTD-PAH (n = 90) they were 92%, 69% and 55%, respectively. After multivariable adjustment, the survival of patients with SSc-PAH was significantly worse compared with the other conditions (P = 0.001). In these patients, the survival estimates were significantly better with initial ERA-PDE5i combination therapy than with initial ERA or PDE5i monotherapy (P = 0.016 and P = 0.012, respectively). CONCLUSIONS: Mortality remains high in patients with CTD-PAH, especially for patients with SSc-PAH. However, for patients with SSc-PAH, our results suggest that long-term survival may be improved with initial ERA-PDE5i combination therapy compared with initial monotherapy.
引用
- Distler O, Ofner C, Huscher D, et al. Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis. Rheumatology (Oxford). 2024. PMID: 37462520. doi:10.1093/rheumatology/kead360
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。